Allarity Therapeutics, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $15.7M
- Price
- $0.984
- % Change (Daily % change from the live per-ticker quote feed.)
- -0.13%
- Volume
- 81.0K
About
Allarity Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new cancer treatments. They utilize a unique "drug response predictor" technology to generate specific companion diagnostics, aiming to identify which patients will best respond to their various oncology therapeutics. The company's portfolio of investigational drugs for various cancers includes: Stenoparib: A poly-ADP-ribose polymerase (PARP) inhibitor currently in Phase 2 clinical trials for ovarian cancer. Dovitinib: A pan-tyrosine kinase inhibitor designed to treat renal cell carcinoma. IXEMPRA: A microtubule inhibitor used in the treatment of metastatic breast cancer. LiPlaCis: A liposomal formulation of cisplatin, undergoing Phase 2 clinical trials for metastatic breast cancer. 2X-111: A liposomal formulation of doxorubicin, also in Phase 2 studies for both metastatic breast cancer and glioblastoma multiforme. Established in 2004, Allarity Therapeutics maintains its headquarters in Cambridge, Massachusetts.
Quick stats
Shares outstanding15.9M
Computed float15.8M
Float / shares99.3%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001860657
Websitehttps://www.allarity.com
AI Summary
AI-generated1/18
minorbullishoperations update
Allarity Provides Update on Key Recent Advances Solidifying Drug Response Predictor® to Drive Stenoparib’s Clinical Development
Allarity Therapeutics provided an update on its Drug Response Predictor (DRP) technology, recent patent awards, and CLIA certification of its in-house lab, which the company says solidify commercial exclusivity of stenoparib.
At AACR 2026, an exploratory analysis of a prior Phase 2 ovarian cancer cohort showed higher pretreatment DRP scores were associated with longer overall survival on twice-daily stenoparib.
The company plans to use DRP-guided patient selection for a potential pivotal trial as stenoparib advances toward FDA approval, and sees external diagnostic partnership opportunities.
A separate Phase 2 trial of stenoparib plus temozolomide in relapsed small cell lung cancer is enrolling at multiple U.S. Department of Veterans Affairs sites.
Red flags
- DRP ovarian cancer analysis is exploratory and may not replicate in future trials
- company notes need for additional financing
- clinical-stage micro-cap with no approved product